Tocilizumab for rheumatoid arthritis
26 results
1 - 26
Tocilizumab for rheumatoid arthritis 
Tocilizumab for rheumatoid arthritis: Cochrane systematic review- Rheumatoid arthritis
- Tocilizumab for thyroid eye disease
- Biologic interventions for fatigue in rheumatoid arthritis
- Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti‐rheumatic drugs for rheumatoid arthritis: A network meta‐analysis
- Combination therapy in rheumatoid arthritis
- Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease‐modifying anti‐rheumatic drugs: a systematic review and network meta‐analysis
- Tocilizumab for giant cell arteritis
- Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics
- Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis
- Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta‐analysis
- Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review
- Chronic diseases and pregnancy
- Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA)
- Interleukin‐receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases
- Adverse effects of biologics: a network meta‐analysis and Cochrane overview
- COVID-19 and other coronavirus infections